BioLineRx (NASDAQ: BLRX) a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has commenced an underwritten ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE